Antibody-Drug Conjugates
![WuXi XDC's $470.5M IPO to Expand Manufacturing Globally](https://pharmtales.com/wp-content/uploads/2023/11/WuXi-XDC-Plans-470.5M-IPO-to-Drive-Global-Manufacturing-Expansion.jpg)
WuXi XDC Plans $470.5M IPO to Drive Global Manufacturing Expansion
WuXi’s spinoff venture, WuXi XDC, is poised to make its debut on the Hong Kong Stock Exchange later this month, ...
![Merck Ends Some ADC Development with Kelun](https://pharmtales.com/wp-content/uploads/2023/10/Merck-Drops-Two-Cancer-ADCs-from-Kelun-Deal-Focuses-on-Daiichi-Sankyo.jpg)
Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo
Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...
![Merck-Daiichi $22B deal for cancer ADCs](https://pharmtales.com/wp-content/uploads/2023/10/Merck-and-Daiichi-join-forces-to-develop-novel-cancer-drugs-in-22B-deal.jpg)
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
![Lilly buys Elahere, boosts ADC portfolio](https://pharmtales.com/wp-content/uploads/2023/10/Lilly-acquires-European-biotech-Elahere-expands-its-ADC-network-and-pipeline-1.jpg)
Lilly acquires European biotech Elahere, expands its ADC network and pipeline
Eli Lilly is actively expanding its involvement in the burgeoning field of antibody-drug conjugates (ADCs) in Europe. Following its recent ...
![Lonza to boost ADC production capacity and hire 180 new staff](https://pharmtales.com/wp-content/uploads/2023/10/Lonza-to-boost-ADC-production-capacity-and-hire-180-new-staff.jpg)
Lonza to boost ADC production capacity and hire 180 new staff
Despite the unexpected departure of Lonza’s CEO last month, the Swiss Contract Development and Manufacturing Organization (CDMO) remains a force ...
![dato-dxd breast cancer trial results, astrazeneca daiichi breast cancer adc, dato-dxd vs trodelvy breast cancer, dato-dxd fda approval status, dato-dxd progression-free survival breast cancer, dato-dxd safety and efficacy breast cancer, dato-dxd her2-low breast cancer](https://pharmtales.com/wp-content/uploads/2023/09/AstraZeneca-and-Daiichi-Reach-Key-Milestone-in-Breast-Cancer-ADC-Trial-Paving-Way-to-Challenge-Gilead.jpg)
AstraZeneca and Daiichi Reach Key Milestone in Breast Cancer ADC Trial, Paving Way to Challenge Gilead
AstraZeneca and Daiichi Sankyo are making a strategic move to challenge Gilead Sciences’ position in the breast cancer arena. They ...
![Seagen, Tukysa, Breast cancer, Antibody drug conjugates, Clinical Data, Pharma, Roche, Kadcyla, Enhertu, Pfizer, HER2](https://pharmtales.com/wp-content/uploads/2023/08/Seagens-Tukysa-Demonstrates-Trial-Victory-in-Breast-Cancer-Amplifying-Roches-Kadcyla-and-Significance-in-Light-of-Pfizers-43B-Acquisition.jpg)
Seagen’s Tukysa Demonstrates Trial Victory in Breast Cancer, Amplifying Roche’s Kadcyla and Significance in Light of Pfizer’s $43B Acquisition
In a strategic move, Pfizer has announced a hefty investment of $43 billion to acquire Seagen, with a keen focus ...
![How Daiichi Sankyo Will Rule the Antibody-Drug Conjugates Market by 2029](https://pharmtales.com/wp-content/uploads/2023/08/Daiichi-Sankyo-to-Dominate-Antibody-Drug-Conjugates-Market-by-2029.jpg)
Daiichi Sankyo to Dominate Antibody-Drug Conjugates Market by 2029
Daiichi has successfully established ADCs (Antibody-Drug Conjugates) as a significant therapeutic approach, overcoming previous years of underwhelming results. Even though ...
![How BCMA-targeted therapies are changing the game for multiple myeloma](https://pharmtales.com/wp-content/uploads/2023/07/How-BCMA-targeted-therapies-are-changing-the-game-for-multiple-myeloma.jpg)
How BCMA-targeted therapies are changing the game for multiple myeloma
Imagine a world where you could treat cancer with a simple injection or infusion, without the need for surgery, chemotherapy, ...
![Lonza Bolsters Antibody-Drug Conjugates Portfolio with Synaffix Acquisition](https://pharmtales.com/wp-content/uploads/2023/06/Lonza-Bolsters-Antibody-Drug-Conjugates-Portfolio-with-Synaffix-Acquisition.jpg)
Lonza Bolsters Antibody-Drug Conjugates Portfolio with Synaffix Acquisition
Lonza, a global manufacturing company acquired Synaffix B.V., a biotechnology company specializing in the advancement of ADCs (antibody-drug conjugates) through ...